Inovio Pharmaceuticals Plunges 29.44% on $25M Offering

Inovio Pharmaceuticals' stock plummeted by 29.44% in pre-market trading on July 4, 2025, marking a significant downturn for the biotechnology company.

Inovio Pharmaceuticals recently announced the pricing of a $25 million public offering, which is expected to close around July 7, 2025. The offering includes the sale of common stock and Series B warrants, with the gross proceeds anticipated to be approximately $25 million. This financial move is part of the company's strategy to raise capital and support its ongoing research and development efforts.

The pricing of the offering at $1.75 per share of common stock and Series B warrants to purchase up to 14,285,715 shares of its common stock reflects the company's efforts to secure additional funding. This capital raise is crucial for Inovio as it continues to advance its pipeline of innovative therapies and vaccines, aiming to address unmet medical needs and improve patient outcomes.